Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Insys Therapeutics, Inc. | insy-ex312_9.htm |
| EX-31.1 - EX-31.1 - Insys Therapeutics, Inc. | insy-ex311_10.htm |
| EX-23.1 - EX-23.1 - Insys Therapeutics, Inc. | insy-ex231_11.htm |
| EX-21.1 - EX-21.1 - Insys Therapeutics, Inc. | insy-ex211_12.htm |
| EX-10.17 - EX-10.17 - Insys Therapeutics, Inc. | insy-ex1017_896.htm |
| 10-K - 10-K - Insys Therapeutics, Inc. | insy-10k_20161231.htm |
Exhibit 32.2
Certification Pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
For purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Insys Therapeutics, Inc., a Delaware corporation (“Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (“Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated: March 31, 2017 |
|
/s/ Dr. Santosh Vetticaden |
|
|
|
Dr. Santosh Vetticaden |
|
|
|
Interim Chief Executive Officer and Chief Medical Officer |
|
Dated: March 31, 2017 |
|
/s/ Darryl S. Baker |
|
|
|
Darryl S. Baker |
|
|
|
Chief Financial Officer |